Hepion Pharmaceuticals, Inc. (OTC:HEPA)
| Market Cap | 663.69K-16.2% |
| Revenue (ttm) | 0 |
| Net Income | -3.19M+76.5% |
| EPS | -0.24+99.5% |
| Shares Out | 11.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,002 |
| Open | 0.08 |
| Previous Close | 0.09 |
| Day's Range | 0.06 - 0.08 |
| 52-Week Range | 0.03 - 0.11 |
| Beta | 1.76 |
| Analysts | Hold |
| Price Target | 70.00(+122707.02%) |
| Earnings Date | Oct 14, 2026 |
About HEPA
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$HEPA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in HEPA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by HEPA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
HEPA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New HEPA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to HEPA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in HEPA
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $8.32 |
Estimated from each fund’s disclosed top holdings × AUM
HEPA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from HEPA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score